TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.
Cohort (n=28,805)
Yes
Does TF-TAVR improve in-hospital outcomes and cost-effectiveness compared to SAVR in younger patients?
A shift from SAVR to TF-TAVR in younger patients appears to be cost-effective with justifiable incremental costs per life saved.
Effect estimate: RR 0.65
Absolute Event Rate: 1.7% vs 1.6%
p-value: p=0.012
Given an estimated life expectancy of 11 to 25 years in this population, the incremental costs per life saved associated with a hypothetical shift from SAVR to TF-TAVR appear justifiable. Nonetheless, individual patient circumstances must always be considered in decision-making.
Kaier et al. (Mon,) conducted a cohort in Severe aortic stenosis (n=28,805). Transfemoral transcatheter aortic valve replacement (TF-TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on In-hospital mortality (RR 0.65, p=0.012). TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.